Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.

Fiche publication


Date publication

avril 2022

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr VERNEREY Dewi, Dr KIM Stephano


Tous les auteurs :
Rousseau B, Boukerma AK, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim S, Bachet JB, Mazard T, Louvet C, Chibaudel B, Vernerey D, Andre T, Hulin A

Résumé

This prospective pharmacokinetic (PK) ancillary study of the TEXCAN phase II GERCOR trial of patients with chemorefractory metastatic colorectal cancer and treated with regorafenib (REGO) investigated correlations between overall survival (OS) and concentrations (C) of REGO and its active metabolites, M-2 and M-5.

Mots clés

Chemorefractory metastatic colorectal cancer, M-2, M-5, Pharmacokinetic, Pharmacological monitoring, Regorafenib, Survival

Référence

Eur J Cancer. 2022 Apr 27;168:99-107